# EXTEND-OP: HCP commentary report

> 25 verified statements (15 from clinicians verified by NPI or staff page) from 3 commentary sources · 4 findings · updated Nov 1, 2026

## Report

- Trial: A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)
- NCT ID: NCT06367972
- Registry: https://clinicaltrials.gov/study/NCT06367972
- Sponsor: M.D. Anderson Cancer Center
- Phase: Phase 2/Phase 3
- Status: Recruiting
- Drugs tested: none (the trial tests no drug)
- Indication: oligoprogressive metastatic disease
- Version: v1.0.0, edition 1
- Accepted: 2026-11-01
- Last checked: 2026-11-01
- Release hash: 283729854d3e357ff13eeea697a0772d4e45a385f0fd9f58cd4167ed961ad6fa

## Counts

- HCP commentary sources screened: 6
- Sources cited by verified statements: 4
- Verified statements: 25
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 15
- Findings: 4
- Named people in screened sources (unnamed speakers and accounts not counted): 5
- Voices cited: 4
- Cited voices identity-verified: 4

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

EXTEND-OP compares local consolidation with next-line systemic therapy in oligoprogressive metastatic disease; sequencing clarification resolved a speaker’s progression-free survival objection. The report cites three radiation oncologists, including a speaker described in the source as a principal investigator. Further debate concerns when deferring next-line systemic therapy has value and which breast-cancer patients might benefit from line preservation. How should treatment delay be distinguished from benefit through the next systemic line, while keeping toxicity and patient selection in view?

## Open Medical Affairs question

How should Medical Affairs distinguish treatment-delay value from benefit through the next systemic line, while preserving toxicity and patient-selection caveats?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The PFS objection became acceptance after the treatment sequence was clarified
- F2. Deferring the next systemic line was valued conditionally, not equated with superior PFS
- F3. Breast-cancer support for line preservation was selective and qualified by contrasting studies
- F4. Investigator enthusiasm concerned patient-centered evidence and colorectal accrual, not demonstrated benefit

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 10 | 9 | 2 | 2 | none recorded | 3 |
| F2 | 5 | 3 | 2 | 1 | none recorded | 3 |
| F3 | 10 | 7 | 1 | 2 | none recorded | 3 |
| F4 | 3 | 3 | 2 | 1 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 2 | 3 | 0 | 0 | 5 | 10 | 4 | 1 post or article, 1 registry | yes |
| F2 | 3 | 1 | 0 | 0 | 1 | 6 | 0 | 1 post or article, 1 registry | yes |
| F3 | 3 | 0 | 0 | 1 | 6 | 12 | 0 | 1 post or article | yes |
| F4 | 2 | 0 | 0 | 0 | 1 | 3 | 0 | 2 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Safety and adverse events (AEs): F1 (6 shared claims), F2 (1 shared claims)
- Population and setting: F1 (2 shared claims), F3 (6 shared claims), F4 (1 shared claims)
- The comparison: F1 (6 shared claims), F2 (4 shared claims), F3 (1 shared claims), F4 (1 shared claims)
- Safety and tolerability: F2 (1 shared claims), F3 (1 shared claims)
- Design and conduct: F1 (2 shared claims), F4 (3 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. The PFS objection became acceptance after the treatment sequence was clarified

An X-thread discussion asked how progression-free survival is assessed across the EXTEND-OP treatment sequence.

The questioner’s clinical role is not stated in the sources reviewed for this edition.

The registry’s endpoint descriptions differ; no full protocol or results publication was available in the sources reviewed for this edition.

Source: X thread, 2025-10-01.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 25 | Paid |
| Trial aspects mapped | 8 | Free |
| Sources with links | 4 | Counts free |
| Speaker attribution for cited voices | 4 | Paid |

## Trial aspects

8 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Safety and adverse events (AEs) | discussed | 6 | 1 |
| Population and setting | discussed | 9 | 2 |
| The comparison | discussed | 9 | 2 |
| Safety and tolerability | discussed | 1 | 1 |
| Design and conduct | discussed | 5 | 3 |
| CURB, RADIANT and AVATAR: selective breast-cancer line preservation | discussed | 9 | 1 |
| Value of deferring next-line therapy and the alternative add-on question | discussed | 4 | 1 |
| Patient-centered endpoints | discussed | 2 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 6 | 3 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2024-09-29 to 2026-10-09
- Cited window: 2025-10-01 to 2026-10-09
- Retrieved: 2026-11-01

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)
- Registry: NCT06367972 (https://clinicaltrials.gov/study/NCT06367972)
- Study IDs: 2024-0070 · NCI-2024-03278 (NCI-CTRP Clinical Registry)
- Sponsor: M.D. Anderson Cancer Center
- Design: Phase 2/Phase 3 · interventional, randomized, single group, phase2, phase3
- Status: Recruiting
- Enrollment: 400 (estimated)
- Start: 2024-06-06 (actual)
- Primary completion: 2028-10-10 (estimated)
- Primary endpoint: Safety and adverse events (AEs) (Through study completion; an average of 1 year.)
- Intervention: Local Consolidation Therapy (procedure)
- Intervention: Next-line Systemic Therapy (procedure)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition do not represent all HCP discussion or establish consensus. Some potentially relevant discussion was not fully assessed, and comments that did not name the trial or used other name variants may be missing.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The CURB, RADIANT and AVATAR figures remain attributed to a speaker’s summaries. Comparisons across these studies do not establish causal effects of earlier treatment, fewer lesions or a particular selection strategy.
- A speaker, described in the source as a principal investigator of EXTEND-OP, discussed anticipated evidence and completed colorectal recruitment. These statements do not establish clinical benefit, safety or recruitment status across every EXTEND-OP cohort.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-11-01: current edition

Last checked for new commentary 2026-11-01. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (25 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (4 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/extend-op-nct06367972
- Agents: POST https://www.erudio.com/api/orders with {"report": "extend-op-nct06367972", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=extend-op-06367972

## Cite

Erudio Health. EXTEND-OP (NCT06367972): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 1, 2026. https://www.erudio.com/reports/extend-op-nct06367972

## Machine access

- JSON: https://www.erudio.com/reports/extend-op-nct06367972.json
- Markdown: https://www.erudio.com/reports/extend-op-nct06367972.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "extend-op-06367972"}`